Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts

Sanofi Pipeline PDF: Dupixent, Lantus, and 2026 Catalysts

This plan frames a Sanofi pipeline pdf-style news brief around current clinical catalysts, with Dupixent as the anchor asset and Lantus as a mature revenue base. It also clarifies the Sanofi Pasteur MSD joint venture structure and why the pipeline matters for analysts and BD teams.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for this topic, with Dupixent and Lantus most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Dupixent was Sanofi's best-selling pharmaceutical product in 2025, cementing its role as the company's commercial anchor.
• Lantus generated 1.7 billion euros in 2025, reflecting its status as a mature legacy product in diabetes care.
• Three recruiting phase 3 trials—NCT05263206 in chronic pruritus, NCT06868212 in chronic spontaneous urticaria, and NCT07076199 comparing insulin icodec to insulin glargine—represent key clinical milestones for pipeline tracking.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Merck & Co., Sanofi, and Sanofi Pasteur reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Dupixent Anchors Sanofi's Immunology Portfolio

Dupixent was Sanofi's best-selling pharmaceutical product in 2025, underscoring its centrality to the company's immunology and dermatology strategy. The drug carries FDA approval for the treatment of atopic dermatitis in patients aged 6 months and older.

Sanofi's dupilumab development program spans multiple active indications. NCT05263206 is a recruiting phase 3 trial evaluating subcutaneous dupilumab for chronic pruritus of unknown origin, while NCT06868212 is a recruiting phase 3 trial testing dupilumab against remibrutinib in chronic spontaneous urticaria inadequately controlled by second-generation antihistamines. Beyond these trials, dupilumab is being studied for bullous pemphigoid, representing potential expansion into rare autoimmune blistering conditions.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for this topic. Expect implications for pricing, access, and launch sequencing.

Lantus: Legacy Revenue Base in Diabetes Care

Lantus generated 1.7 billion euros in revenue for Sanofi in 2025. Lantus is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

NCT07076199 is a recruiting phase 3 trial comparing a weekly insulin icodec formulation to daily insulin glargine, both combined with insulin aspart, in adults with type 1 diabetes. This trial provides a direct head-to-head comparison between the two insulin regimens and represents a key watch point for analysts tracking competitive dynamics in the insulin market.

IntelligenceStrategic Takeaways▾

Dupixent was Sanofi's best-selling pharmaceutical product in 2025 , cementing its role as the company's commercial anchor. Lantus generated 1.7 billion euros in 2025, reflecting its status as a mature legacy product in diabetes care. Three recruiting phase 3 trials— NCT05263206 in chronic pruritus , NCT06868212 in chronic spontaneous urticaria, and NCT07076199 comparing insulin icodec to insulin glargine—represent ke

Sanofi Pasteur MSD: A 50/50 Joint Venture, Not a Parent Company

A frequent source of confusion in pharma ownership discussions, Sanofi Pasteur MSD is a joint venture owned on a 50/50 basis by Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Neither Merck nor Sanofi owns the other; they co-own the vaccines joint venture equally. This structure matters for BD and licensing teams assessing vaccine-related partnerships or asset transfers involving either parent company.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source and 1 peer-reviewed source.

What to Watch Next in the Sanofi Immunology Pipeline

For analysts and BD teams, three recruiting trials represent active clinical milestones. NCT05263206 in chronic pruritus remains recruiting, signaling clinical interest in dupilumab for non-dermatitis itch indications. NCT06868212 comparing dupilumab to remibrutinib in chronic spontaneous urticaria is actively recruiting. NCT07076199 comparing insulin icodec to insulin glargine in type 1 diabetes is recruiting, offering a competitive lens on long-acting insulin formulations. These trials frame the near-term catalyst calendar for competitive benchmarking across Sanofi's dermatology and diabetes portfolios.

Frequently Asked Questions

Related profiles

• Sanofi
• dupixent
• LANTUS
• Sanofi Pasteur
• Sanofi Pasteur MSD

Related coverage

• Arcus Biosciences pipeline update: casdatifan, quemliclustat, domvanalimab
• Syndax pipeline update: Revuforj and Niktimvo catalysts to watch
• Tillomed Laboratories update: pipeline, melphalan and next catalysts